Jefferies Backs Relmada, BTIG Turns Bullish on Invivyd
Jefferies and BTIG start coverage on Relmada and Invivyd with Buy ratings, citing pipeline shifts, strong assets, and large market potential.
/ 907 items
#Healthcare↓
FDA Approves New Heart Drug MYQORZO for Obstructive HCM
The FDA has approved Cytokinetics' MYQORZO (aficamten), a groundbreaking treatment for adults with symptomatic obstructive hypertrophic cardiomyopathy to improve heart function and reduce symptoms.
Trump Administration Secures Drug Price Cuts from Nine Major Pharmaceutical Companies
Nine pharmaceutical giants including Merck and GSK agree to slash U.S. drug prices to match other wealthy nations under new Trump administration deals, offering discounts up to 70%.
Disc Medicine Stock Drops Amid FDA Official's Questions on Drug Effectiveness
Disc Medicine (IRON) shares fall 14% after FDA official questions bitopertin's effectiveness for rare blood disorder, though analysts maintain buy ratings and approval pathway optimism.
Altimmune's MASH Drug Shows Promise in Extended Trial Despite Mixed Signals
Altimmune (ALT) reports 48-week results for pemvidutide in MASH trial, showing continued weight loss and liver fibrosis improvements, though some measures weakened from earlier data.
Spero Therapeutics Secures $25M Milestone Payment from GSK Partnership
Spero Therapeutics announces $25 million milestone payment following GSK's FDA resubmission for tebipenem HBr antibiotic treatment for urinary tract infections.